RecruitingPhase 3NCT06549686

A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee

A Phase III Study Evaluating the Efficacy and Safety of CLS2901C in Patients With Osteoarthritis of the Knee


Sponsor

CellSeed Inc.

Enrollment

96 participants

Start Date

Oct 20, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate the efficacy and safety of CLS2901C human allogenic chondrocyte sheets used in the osteotomy + RMSC group compared to in the osteotomy alone group of patients with osteoarthritis of the knee (OAK).


Eligibility

Min Age: 20 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called CLS2901C (human [allogeneic] chondrocyte sheets) for people with osteoarthritis of the knee. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 20 Years to 79 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCLS2901C (human [allogeneic] chondrocyte sheets)

CLS2901C (human \[allogeneic\] chondrocyte sheets)


Locations(6)

Ebina General Hospital/Ebina Medical Plaza

Ebina, Kanagawa, Japan

Tokai University Hospital

Isehara, Kanagawa, Japan

Yokohama Sekishinkai Hospital

Yokohama, Kanagawa, Japan

Yokohama City University Medical Center

Yokohama, Kanagawa, Japan

Yokohama Minami Kyousai Hospital

Yokohama, Kanagawa, Japan

Juntendo University Hospital

Bunkyō-Ku, Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06549686


Related Trials